Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHRQ Comparative Effectiveness Funding Doubled In 2008 Budget Bills

Executive Summary

Funding for medical product comparative effectiveness research within the HHS Agency for Healthcare Research and Quality would increase to $30 million in fiscal year 2008 appropriations legislation pending in both the House and Senate

You may also be interested in...



New Antidiabetics Need Head-To-Head Trials With Existing Regimens – AHRQ

New insulin therapies need to be compared to traditional insulin therapies in studies with regimens that resemble usual clinical practice, the Agency for Healthcare Research and Quality says

New Antidiabetics Need Head-To-Head Trials With Existing Regimens – AHRQ

New insulin therapies need to be compared to traditional insulin therapies in studies with regimens that resemble usual clinical practice, the Agency for Healthcare Research and Quality says

Senate passes HHS funding bill

The Senate Oct. 23 passed the HHS and labor appropriations bill by 75-19, an amended version of the House bill (H.R. 3043), which passed in July by a 276-140 vote. The bills propose increasing funding for the HHS Agency for Healthcare Research and Quality to $329.6 million for FY 2008, a $10.6 million increase from FY 2007. Within AHRQ's funding is an increase for comparative effectiveness research from $15 million in FY 2007 to $30 million in FY 2008 (1"The Pink Sheet" July 16, 2007, p. 23). Congress is authorized to allocate up to $50 million for comparative effectiveness research under the Medicare Modernization Act...

Related Content

UsernamePublicRestriction

Register

PS048557

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel